Click here to view the United Healthcare (UHC) Medical Policy Updates » December 2024 United…
BCBS Tennessee Medical Policy Updates – April 2024
Click here to view the Blue Cross Blue Shield BCBS Tennessee Medical Policy Updates »
April 2024 BCBS Tennessee Medical Policy Updates:
- Abatacept
- Ado-Trastuzumab Emtansine
- Aflibercept
- Alemtuzumab
- Atezolizumab
- Balloon and Self-Expanding Absorptive Ostial Dilation for Treatment of Chronic Sinusitis
- Belinostat
- Benralizumab
- Bevacizumab for the Treatment of Neoplastic Disease
- Blinatumomab
- Brentuximab Vedotin
- Burosumab-twza
- C1 Esterase Inhibitor (Berinert®)
- C1 Esterase Inhibitor (Human) – Cinryze®
- C1 Esterase Inhibitor (recombinant) – Ruconest®
- C1 Esterase Inhibitor Subcutaneous (Human) (Haegarda®)
- Calaspargase Pegol-mknl
- Certolizumab Pegol
- Collagenase (Xiaflex®)
- Complementary and Alternative Medicine
- Corticotropin Therapy
- Crizanlizumab-tmca
- Degarelix
- Denosumab (Prolia®)
- Denosumab (Xgeva®)
- Digital Breast Tomosynthesis (3D Mammogram)
- Durvalumab
- Ecallantide
- Emapalumab-lzsg
- Endometrial Ablation
- Endothelial Keratoplasty
- Exagamglogene Autotemcel (Casgevy™)
- Fam-trastuzumab Deruxtecan-nxki
- Gene Expression Profile Analysis for Prostate Cancer Management
- Genetic Testing for the Diagnosis of Inherited Peripheral Neuropathies
- Givosiran
- Golimumab for Intravenous Infusion
- Icatibant
- Infliximab
- Intraoperative Radiation Therapy (IORT)
- Ipilimumab
- Laser Assisted Uvulopalatoplasty (LAUP)
- Lipectomy and Liposuction for Lymphedema
- Lovotibeglogene Autotemcel (Lyfgenia®)
- Mentoplasty (Chin Augmentation, Genioplasty)
- Mepolizumab
- Methoxy Polyethylene Glycol-Epoetin Beta (Mircera®)
- Mitomycin Gel
- Natalizumab
- Naxitamab-gqgk (Danyelza®)
- Nivolumab
- Ocrelizumab
- Omalizumab
- Paclitaxel (Protein-Bound)
- Pegfilgrastim
- Pembrolizumab
- Pemetrexed
- Pertuzumab
- Progenitor Cell Therapy for the Treatment of Damaged Myocardium Due to Ischemia
- Radioembolization for Primary Tumors of the Liver and Metastatic Tumors to the Liver
- Ranibizumab
- Reslizumab
- Rituximab and Hyaluronidase Human Injection
- Rituximab Products (Rituxan®, Rituximab-abbs [Truxima®],Rituximab-arrx [Riabni™] and Rituximab-pvvr [Ruxience®]) (Non-Oncology Indications)
- Rituximab Products (Rituxan®, Rituximab-abbs [Truxima®],Rituximab-arrx [Riabni™] and Rituximab-pvvr [Ruxience®]) (Oncology Indications)
- Secukinumab (Cosentyx®)
- Sutimlimab-jome (Enjaymo™)
- Tafasitamab-cxix
- Teprotumumab-trbw
- Tezepelumab-ekko (Tezspire™)
- Tildrakizumab-asmn
- Tocilizumab (Intravenous)
- Transcranial Magnetic Stimulation (TMS)
- Trastuzumab
- Trastuzumab and Hyaluronidase-oysk
- Treatment for Lyme Disease
- Ublituximab-xiiy (Briumvi™)
- Ustekinumab
- Vedolizumab
Click here to view the Blue Cross Blue Shield BCBS Tennessee Medical Policy Updates »
How Does Policy Alerts Work?
Policy Alerts’ medical policy monitoring and alerts software continuously monitors Commercial, Medicare, and Medicaid coverage information to keep you up-to-date on coverage changes in real-time.
Policy Alerts’ software locates relevant Payer medical policies and coverage information from across the web. This software monitors that information for updates and changes while also searching for new medical policies and coverage information. Whenever changes occur, Policy Alerts immediately sends out an email notification containing a summary of what has changed.
Clients can access their medical policies and payer coverage summary on the interactive Policy Alerts dashboard. Never miss another important insurance carrier medical policy review or coverage decision update again!
✓ Thousands of subscribers ✓ Easy setup
Related Posts
